TIDM4BB 
 
14 June 2023 
 
                                 4basebio PLC 
                         ("4basebio" or the "Company") 
                      Annual General Meeting 2023 ("AGM") 
 
4basebio Plc (AIM: 4BB), an innovation driven biotechnology company enabling 
and accelerating development of advanced therapy medicinal products (ATMPs) 
through its high performant synthetic DNA products and non-viral, cell 
targeting nucleic acid delivery platform announces that all of the resolutions 
proposed at its Annual General Meeting held earlier today were duly passed. 
 
The Company also wishes to again draw attention to the investor meeting being 
held on 16 June 2023, through the Investor Meet Company platform at 10.00am. 
Investors can sign up to Investor Meet Company for free and register interest 
here: 
 
https://www.investormeetcompany.com/register-investor 
 
For further enquiries, please contact: 
 
4basebio PLC                                                     +44 (0)12 2396 
7943 
 
Heikki Lanckriet 
 
Nominated Adviser                                          +44 (0)20 7213 0880 
 
Cairn Financial Advisers LLP 
 
Jo Tuner / Sandy Jamieson 
 
Broker                                                                +44 (0)20 
7220 0500 
 
finnCap Ltd 
 
Geoff Nash/Richard Chambers/Charlotte Sutcliffe 
 
Lionsgate Communications (Media Enquiries)                 +44 (0)77 91892509 
Jonathan Charles 
 
Notes to Editors 
 
About 4basebio 
 
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focussed 
on accelerating the development of advanced therapy medicinal products (ATMPs) 
through its high performant synthetic DNA products and non-viral, cell 
targeting nucleic acid delivery platform. The Company' objective is to become a 
market leader in the manufacture and supply of high quality synthetic DNA 
products for research, therapeutic and pharmacological use as well as 
development of target specific non-viral vectors for the efficient delivery of 
payloads in patients. The company is offering GMP compliant DNA starting 
materials suitable for use in AAV viral vector production as well as mRNA 
vaccine and therapeutics production. 
 
 
 
END

(END) Dow Jones Newswires

June 14, 2023 07:52 ET (11:52 GMT)

4basebio (LSE:4BB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas 4basebio.
4basebio (LSE:4BB)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas 4basebio.